LevTech Lifesciences

About LevTech Lifesciences

LevTech Lifesciences, headquartered in Sydney, New South Wales, Australia, is a medical device company focused on extending the lifespan of heart valve replacements without necessitating anticoagulants. Founded in 2016, the company aims to revolutionize the treatment of heart valve diseases by developing innovative polymeric heart valves. These investigational valves are not available for sale and are not FDA approved, with their clinical safety and efficacy yet to be demonstrated.

Core Business & Key Technologies

LevTech Lifesciences specializes in the development of polymeric heart valves. Its proprietary polymeric materials are uniquely synthesized to withstand blood clot formation, calcification, and biodegradation. The company employs innovative designs optimized through computational modeling to maximize hydrodynamic performance for various patient groups. Additionally, automated manufacturing processes enable scalability, product diversity, short production time, and high precision.

Market Position & Strengths

LevTech Lifesciences holds a promising position in the medical device industry, particularly in the field of heart valve replacements. Its unique approach to developing polymeric heart valves that do not require anticoagulants addresses a significant unmet need in the market. The company's team comprises experienced professionals, including Dr. Sina Naficy, CTO, who holds a PhD in Materials Engineering, and Dr. David S. Winlaw, a cardiothoracic surgical innovator and experienced neonatal surgeon. With the support of external funding and recognition, LevTech Lifesciences is well-positioned to advance its technology and potentially transform the landscape of heart valve replacement therapies.

Contact Information